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The tumor suppressor function of the promyelocytic leukemia (PML) protein was first
identified as a result of its dysregulation in acute promyelocytic leukemia, however, its
importance is now emerging far beyond hematological neoplasms, to an extensive range
of malignancies, including solid tumors. In response to stress signals, PML coordinates the
regulation of numerous proteins, which activate fundamental cellular processes that sup-
press tumorigenesis. Importantly, PML itself is the subject of specific post-translational
modifications, including ubiquitination, phosphorylation, acetylation, and SUMOylation,
which in turn control PML activity and stability and ultimately dictate cellular fate. Improved
understanding of the regulation of this key tumor suppressor is uncovering potential oppor-
tunities for therapeutic intervention.Targeting the key negative regulators of PML in cancer
cells such as casein kinase 2, big MAP kinase 1, and E6-associated protein, with specific
inhibitors that are becoming available, provides unique and exciting avenues for restoring
tumor suppression through the induction of apoptosis and senescence.These approaches
could be combined with DNA damaging drugs and cytokines that are known to activate
PML. Depending on the cellular context, reactivation or enhancement of tumor suppres-
sive PML functions, or targeted elimination of aberrantly functioning PML, may provide
clinical benefit.
Keywords: PML, E6AP, BMK1, CK2, KLHL20, tumour suppression, targeted anti-cancer therapy, small molecule
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INTRODUCTION
The promyelocytic leukemia (PML) gene was initially described in
the pathogenesis of Acute Promyelocytic Leukemia (APL), where
it fuses with the Retinoic Acid Receptor α (RARα) gene as a conse-
quence of the chromosomal translocation t (15;17). The resultant
PML-RARα fusion oncoprotein acts in a dominant negative fash-
ion over wild type (wt) PML, as reiterated in a mouse model (Rego
and Pandolfi, 2001); where malignancy manifests from a differen-
tiation blockage of granulocyte precursors which is compounded
by an enhanced self-renewal (de Thé and Chen, 2010). All-trans
retinoic acid (ATRA) and arsenic trioxide (As2O3) were empiri-
cally identified to provoke a profound therapeutic response against
APL, before the molecular pathogenesis of the disease was estab-
lished (Huang et al., 1988; Borrow et al., 1990; de Thé et al., 1990;
Sun et al., 1992) and unravelling intricacies of their mode of action
toward PML-RARα is ongoing. The intense research that followed
the landmark discovery linking PML to APL pathogenesis, revealed
that PML acts as a tumor suppressor in many other cancer types
and is a master regulator of major cellular processes.
Promyelocytic leukemia comprises multiple isoforms, which
predominantly localize to the nucleus (Bernardi and Pandolfi,
2007; Carracedo et al., 2011). In response to various stress sig-
nals, PML forms distinct matrix-associated structures in the
nucleoplasm, called PML nuclear bodies (NBs) (otherwise known
as PML-NBs, POD, ND10) (Bernardi and Pandolfi, 2007; Car-
racedo et al., 2011). Over 70 proteins are known to co-localize
with PML in the NBs, mainly in a transient manner (Bernardi
and Pandolfi, 2007; Carracedo et al., 2011). PML-NBs mediate the
post-translational modification of target proteins and in a spatio-
temporal manner coordinate a diverse range of specific cellular
functions, including gene transcription, DNA repair, apoptosis,
senescence, and anti-viral response (Dellaire and Bazett-Jones,
2004; Geoffroy and Chelbi-Alix, 2011). In APL, the expression
of PML-RARα is associated with numerous, disorganized nuclear
microstructures instead of the normal PML-NBs (Koken et al.,
1994; Weis et al., 1994).
A well-defined downstream effector pathway of PML
(Salomoni et al., 2008, 2012) involves the key tumor suppressor
p53. In response to stress, PML promotes the activation and stabi-
lization of p53 by protecting it from its major inhibitor Mdm2, and
facilitating key post-translational modifications (Louria-Hayon
et al., 2003; Bernardi et al., 2004; Alsheich-Bartok et al., 2008).
Intriguingly, PML is also a transcriptional target of p53 (de
Stanchina et al., 2004), implying that these two important tumor
suppressors impact on each other through a positive regulatory
loop. However, transcription is not the major dictator of altered
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PML levels (Gurrieri et al., 2004a) and in this review, we scruti-
nize our current knowledge regarding PML regulation. We suggest
that the careful analysis of key upstream molecules that act upon
PML in different cancer types will be a strategic approach toward
rationally defining targets for the design of specific anti-cancer
therapies with a capacity to restore functional PML.
LOSS OF PML FUNCTION PROMOTES TUMORIGENESIS
The original studies by Koken et al. (1995) and Terris et al. (1995)
revealed that PML expression is altered during the process of onco-
genic transformation. In the subsequent studies PML protein levels
were identified to be down-regulated (complete or partial loss)
in a wide spectrum of human cancers, beyond APL, including
additional hematological neoplasms: non-Hodgkin lymphomas
(77%), carcinomas of the: prostate (92%), lung (58%), colon
(47%); and breast (53%); tumors of the central nervous sys-
tem (CNS; 73%) and germ cells (85%) (Gurrieri et al., 2004a);
stomach (Lee et al., 2007), lung small cells (Zhang et al., 2000);
and sarcomas of the soft tissues (Vincenzi et al., 2010). Per-
tinently, downregulation of PML is frequently associated with
increased tumor grade and highly aggressive disease in some
tumor types, e.g., prostate and breast adenocarcinomas (Rego
and Pandolfi, 2001). PML tumor suppressive functions have been
validated in a number of genetically engineered mouse cancer
models. PML deficiency in the context of PTEN+/−mice, resulted
in the invasive adenocarcinoma of the colon (Trotman et al.,
2006). Dosage-dependent PML loss correlated with the num-
ber and size of colonic polyps. Further, the tumor burden and
aggressiveness of KrasG12D-induced non-small cell lung can-
cer (NSCLC) was significantly increased in the absence of PML
(Scaglioni et al., 2006). Most recently, PML tumor suppressive
capacity was demonstrated in a mouse model of B-lymphoma
driven by c-Myc (Wolyniec et al., 2012b) and in the context of
mutant p53 (Haupt et al., 2013). These fundamental in vivo stud-
ies, together with detailed molecular analysis in vitro, have revealed
major roles of PML in the induction of apoptosis and cellular
senescence.
MULTIPLE MECHANISMS OF PML REGULATION
Loss of PML protein frequently occurs in cancers without cor-
relation to PML mRNA levels, or gene mutation, but rather at a
post-translational level (Gurrieri et al., 2004a,b). Importantly, pro-
teasome inhibitor treatment of selected tumor cell lines lacking
detectable PML levels (Gurrieri et al., 2004a), was able to restore
PML expression. This provided a rationale for restoration of PML
expression at the protein level. Molecular pathways that promote
PML degradation are therefore potential targets for its restoration.
Further, PML degradation is regulated by post-translational mod-
ifications including ubiquitination, phosphorylation, acetylation,
SUMOylation, and isomerization (Figure 1); and each of these
pathways has been implicated in various types of cancer (Table 1)
and offers therapeutic potential.
UBIQUITINATION
The finding that PML expression is largely regulated in cancer cells
at the level of proteasomal degradation (Gurrieri et al., 2004a)
triggered a search for the relevant E3 ligases that regulate the ubiq-
uitination and subsequent degradation of PML in normal and
FIGURE 1 | Promyelocytic leukemia is regulated by multiple
mechanisms. Post-translational modifications such as phosphorylation,
SUMOylation, ubiquitination, acetylation, isomerization by indicated
proteins affect PML stability. Cytokines such as IFNs and IL-6 are known to
activate PML at the transcriptional level via JAK-STAT signaling. Blue arrows
indicate positive and brown negative effect on PML.
cancer cells. In cancer cells the normal regulation of PML turnover
is likely to become corrupted leading to destabilization of PML as
a mechanism of evading tumor suppression (Chen et al., 2012b).
E3 ligases able to promote the degradation of PML-RARα are also
of obvious therapeutic value.
In a search for the key E3 ligase of PML we found that the E6-
associated protein (E6AP) is a physiological E3 ubiquitin ligase
of PML, and showed increased PML expression in multiple tis-
sues of E6AP KO mice. One of the functional implications of this
finding was that lymphoid cells derived from E6AP deficient mice
were more susceptible to DNA-damage induced apoptosis, asso-
ciated with enhanced accumulation of PML-NBs (Louria-Hayon
et al., 2009). A more direct demonstration linking the E6AP-PML
axis to cancer was evident in our recent study of Myc-driven
B-cell lymphoma. We found that a loss of one E6AP allele was
sufficient to attenuate B lymphomagenesis through the restora-
tion of PML expression and induction of cellular senescence.
Importantly, E6AP levels were elevated and associated with PML
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Table 1 | Summary of PML modifications implicated in various human cancers.
Type of PML modification Cancer type PML gain (+) or loss(−) Reference Section in the text
Ubiquitination by E6AP B-cell lymphoma − Wolyniec et al. (2012b) Section “Ubiquitination”
Phosphorylation by CK2 NSCL cancer − Scaglioni et al. (2006) Section “Phosphorylation”
SUMOylation by PIAS1 NSCL cancer − Rabellino et al. (2012) Section “SUMOylation”
Ubiquitination by KLHL20 Prostate cancer − Yuan et al. (2011) Section “Ubiquitination”
Phosphorylation by ERK2/Pin1 Breast cancer − Lim et al. (2011) Section “Phosphorylation”
Unknown mechanism Breast cancer + Carracedo et al. (2012) Section “Targeting GOF PML Activities
in Non-Hematopoietic Malignancies”
Mutant p53 context Colon cancer + Haupt et al. (2009) Section “Targeting GOF PML Activities
in Non-Hematopoietic malignancies”
Reference to the section in the text and to the original publication is listed.
downregulation in more than half of the human B-cell lymphomas
examined (Wolyniec et al., 2012b).
Another E3 ligase that is frequently elevated in various cancers
is UHRF1 (ubiquitin-like with PHD and RING finger domains).
UHRF1 was demonstrated to target PML for degradation by medi-
ating its polyubiquitination in human umbilical vein endothe-
lial cells (HUVEC) and cancer cell lines (Guan et al., 2012).
The ubiquitin ligase ring finger protein 4 (RNF4) selectively
targets poly-SUMOylated PML (see SUMOylation) (Lallemand-
Breitenbach et al., 2008; Tatham et al., 2008). This process is a
key mechanism of action of As2O3 resulting in the degradation
of PML and PML-RARα in APL (see Targeting PML-RARα to
Treat Acute Promyelocytic Leukemia). In addition to proteasomal
degradation, autophagy also mediates the degradation of PML-
RARα induced by ATRA and As2O3 (Boe and Simonsen, 2010).
The ubiquitin-binding adaptor protein p62/SQSTM1 recognizes
specific poly-ubiquitinated proteins including PML-RARα and
directs them to autophagosomes for degradation (Pankiv et al.,
2007; Wang et al., 2011).
In vitro studies have demonstrated that the RING finger E3 lig-
ase SIAH-1/2 binds the coil–coil domain of PML, via its substrate-
binding domain (SBD), and promotes the proteasomal degrada-
tion of PML and PML-RARα (Fanelli et al., 2004). An interesting
study by Yuan et al., revealed a crucial role for the substrate adaptor
protein KLHL20 of the Cullin 3-based ubiquitin ligase, in the reg-
ulation of PML in response to hypoxia, during tumor progression
of prostate cancer. HIF-1α was found to induce KLHL20 pro-
moting the ubiquitination and degradation of PML (Yuan et al.,
2011).
PHOSPHORYLATION
Coordinated phosphorylation and isomerization appears to be a
prerequisite for ubiquitin-mediated destruction of PML, a process
involving a number of kinases. In response to hypoxia (as men-
tioned in see Ubiquitination), induction of KLHL20 by HIF-1α
results in PML turnover. This requires the prior coordinated phos-
phorylation of PML by CDK1/2, followed by isomerization of the
phosphorylated PML by the peptidyl-prolyl cis-trans isomerase,
Pin1. This cascade is involved in cell transformation, migration,
angiogenesis, and survival of mouse xenografts in vivo. Most
importantly, the HIF-1α/KLHL20/Pin1 axis is upregulated in high
grade aggressive and chemoresistant human prostate lesions and
correlated with PML loss (Yuan et al., 2011).
Another example of this sequential PML preconditioning
occurs with the extracellular signal regulated kinase 2 (ERK2),
which is able to localize to the PML-NBs in breast cancer cells
(MDA-MB-231), phosphorylate PML at two sites (S403 and S505),
resulting in the recruitment of Pin1, and subsequent proteasomal
degradation of PML by yet to be identified E3 ligase (Lim et al.,
2011). Addition of hydrogen peroxide was capable of attenuating
the association between PML and Pin1 to maintain PML levels.
On the other hand, IGF-1 reduced PML levels in a Pin1 depen-
dent manner, which enhanced cell migration (Reineke et al., 2010).
Although ERK2 and Pin1 are frequently elevated in many cancers,
the link to reduced PML levels in vivo is yet to be demonstrated.
Phosphorylation priming of PML has also been described with-
out associated isomerization, however whether this second event
is also important remains to be addressed. PML phosphorylation
at multiple sites by casein kinase 2 (CK2), was shown by the ele-
gant work of Scaglioni et al. (2006), to promote its proteasomal
degradation, although the identity of the ubiquitin E3 ligase that
is involved remains to be discovered. Further, analysis of NSCLC
patient derived samples and cell lines, revealed that reduced PML
levels directly correlated with increased CK2 activity, consistent
with the relevance of this pathway to lung tumorigenesis (Scaglioni
et al., 2006). Big MAP kinase 1 (BMK1) also phosphorylates PML
at two sites: S403 and T409 (Yang et al., 2010). Mutational analy-
sis demonstrated that BMK1 drives suppression of PML directly
through its phosphorylation. Activation of BMK1 by its upstream
MEK5 kinase results in the translocation of BMK1 from the cytosol
to the PML-NBs (Yang et al., 2010). It was further demonstrated
that activated BMK1 interferes with the formation of PML-Mdm2
complex, resulting in the suppression of p53 (Yang et al., 2012).
ACETYLATION
The acetylation of PML represents an additional post-translation
mechanism regulating PML. Treatment of HeLa cells with the
HDAC (histone deacetylase) inhibitor, trichostatin A (TSA)
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resulted in increased acetylation of PML leading to efficient
induction of apoptosis (Hayakawa et al., 2008). Importantly
an acetylation-defective PML mutant renders cells refractory to
HDAC inhibitor-induced cell death. The acetylation of PML could
be enhanced by p300 acetylase. Interestingly the increase of PML
acetylation was associated with the increase in the SUMOylation
(Hayakawa et al., 2008). Hence it has been suggested that acetyla-
tion of PML may be a prerequisite for subsequent SUMOylation.
It remains to be shown whether activation of PML by new gener-
ation HDAC inhibitors, currently under investigation, represents
a key molecular event associated with clinical response.
SUMOylation
The addition of small ubiquitin-like molecule (SUMO) to PML
is essential for PML-NB formation and maturation, and may
also mark PML for ubiquitination. SUMO may either be non-
covalently bound to PML through the SUMO binding domain
(Shen et al., 2006), or covalently attached by an E1, E2, and E3-
ligase enzymatic cascade (Shen et al., 2006). PML SUMOylation
also facilitates the recruitment of partner proteins to NBs and in
turn their own SUMOylation (Shen et al., 2006; Bernardi and Pan-
dolfi, 2007). Support of SUMOylation as key modification of PML
is based on a number of studies. (Campagna et al., 2011) described
a novel function for the histone deacetylase, SIRT1, in facilitating
PML SUMOylation. The melanoma antigen gene A2, MageA2,
interacts with PML isoform IV and significantly attenuates the
SUMOylation and acetylation of PML, which in turn affects p53-
mediated cellular senescence (Peche et al., 2012). The E3 SUMO
ligase, protein inhibitor of activated STAT-1 (PIAS1), SUMOylates
PML,and promotes the recruitment of CK2 to phosphorylate PML
on S517 and consequently its degradation (Peche et al., 2012).
PIAS1 regulates PML in NSCL cancer (Peche et al., 2012), and
it has been implicated in As2O3-mediated degradation of PML-
RARα in APL (Rabellino et al., 2012). Overall, the studies described
above suggest a cascade of post-translational modifications involv-
ing phosphorylation, isomerization, and SUMOylation, regulating
PML turnover (Chen et al., 2012b).
CYTOKINE-DEPENDENT REGULATION OF PML
There is growing evidence highlighting the importance of
paracrine signaling in the regulation of PML whereby its tran-
scription is controlled by interferons (IFNs), specific cytokines
involved in anti-viral responses, immune-surveillance as well
as anti-proliferative processes, which are known to be potent
inducers of PML (Chelbi-Alix et al., 1995; Lavau et al., 1995;
Stadler et al., 1995; Der et al., 1998). For example, IFNβ has
been recently shown to induce cellular senescence, a key anti-
cancer mechanism, via a PML-induced mechanism (Chiantore
et al., 2012). In addition, genotoxic drugs such as etoposide
trigger cellular senescence in normal and cancer cells via per-
sistent activation of Janus kinase/signal transducer and activa-
tor of transcription (JAK/STAT) signaling and expression of
IFN-stimulated genes including PML (Hubackova et al., 2010;
Novakova et al., 2010). This is particularly interesting in the con-
text of senescence-associated secretory phenotype (SASP), which
constitutes an integral part of the paracrine/autocrine regulation
of tumor suppression. Furthermore, PML was recently shown to
be regulated by interleukin-6 (IL-6) through a molecular signal-
ing pathway mediated by NFκB and JAK-STAT (Hubackova et al.,
2012). Since IL-6 is a prototypical cytokine involved in cellular
senescence, it is tempting to speculate that PML and IL-6 exist
in a positive regulatory loop driving oncogenic and DNA-damage
induced senescence. This would in turn lead to secretion of IL-6
and IFNs that would further sustain activation of PML.
THERAPIES TO RESTORE PML TUMOR SUPPRESSION
A strategic approach to treating malignancies in which PML tumor
suppressor activity has been reduced or lost through aberrant
degradation, is to target those degradation pathways. However, in
some contexts corrupted PML may provide a survival mechanism
for disease and therapeutic benefit may result from its inhibition
and will be discussed in Section “Therapies to Target Oncogenic
PML Activities.”
THERAPIES DIRECTED TO INHIBITING PML UBIQUITINATION
In our recent study we demonstrated that E6AP elevation is fre-
quently found in human B-cell lymphomas and is associated with
PML downregulation (Wolyniec et al., 2012b). By using Myc-
induced mouse model of lymphomagenesis and human B-cell
lymphoma cell lines, we demonstrated that E6AP haploinsuffi-
ciency in mice or siRNA mediated inhibition of E6AP in human
cells, is sufficient to restrain tumor development by inducing
PML-dependent cellular senescence and preventing expansion of
pre-leukemic B-cells. These observations provide the basis for
considering E6AP as a promising anti-cancer target (Figure 2).
Interestingly,a natural product-like macrocyclicN -methyl peptide
inhibitor against E6AP has been synthesized by random non-
standard peptides integrated discovery (RaPID) (Yamagishi et al.,
2011). This peptide inhibitor, or other inhibitors of E6AP, can be
used to test the possibility of relieving PML from proteasomal
destruction in cancers where E6AP is elevated such as prostate
adenocarcinoma and B-lymphoma (Srinivasan and Nawaz, 2011;
FIGURE 2 | Potential approaches aiming at restoration of PML-induced
tumor suppression. Major therapeutic targets and their inhibitors are
shown on top and potential combinatorial treatments at the bottom.
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Wolyniec et al., 2012b). Another therapeutic strategy could be
to target Culin-3/KLHL20 mediated PML ubiquitination using
a recently described Cullin-family E3 ligase inhibitor, MLN4924
(Soucy et al., 2009; Chen et al., 2012b). Although this inhibitor
has been shown to exhibit potent anti-cancer activity by target-
ing NEDD8, it remains to be demonstrated whether PML is also
involved in this mechanism.
THERAPY DIRECTED TO INHIBITING PML PHOSPHORYLATION
Scaglioni et al. (2006) demonstrated that the reactivation of PML
in vivo could be achieved in established lung cancer xenotrans-
plants, with emodin, a pharmacological inhibitor of CK2 kinase
(Figure 2). Although emodin exerts its effect through multiple
pathways, this approach resulted in substantial suppression of
growth that could be attributed to specific elevation of PML.
Emodin treatment has previously been shown to increase the sen-
sitivity of HeLa cells to As2O3 cytotoxicity through the generation
of ROS, however the role of PML was not explored in this model
(Yi et al., 2004).
Another very convincing strategy aimed at restoration of PML
tumor suppression has been described in the elegant study by
Yang et al. (2010) (Figure 2). By using a newly developed BMK1
inhibitor (XMD8-92), the authors were able to demonstrate effi-
cient anti-tumor effect in vitro and in multiple xenotransplants
in vivo, which was achieved by specific restoration of PML and
downstream activation of p21. In their subsequent study they pro-
vided detailed explanation for the mechanism of BMK1 inhibitor
by linking it to p53 activation (Yang et al., 2012).
COMBINATORIAL THERAPIES TO PROMOTE PML ACTIVATION
Importantly, PML stability can be greatly enhanced by genotoxic
drugs and HDAC inhibitors as well as cytokines such as IL-6 and
IFNs. Therefore it is very likely that the right combinations of
various PML activating strategies may translate to effective ther-
apeutic outcomes (Figure 2). For example, treatment of cancer
cells with etoposide triggers PML-induced senescence by engag-
ing JAK/STAT pathway (Hubackova et al., 2010). This provides a
rationale for a combination treatment of cancer cells with agents
to stabilize PML such as emodin, XMD8-92, or anti-E6AP N -
methyl peptide combined with DNA damaging agents and pro-
senescence cytokines (Acosta and Gil, 2012). Such an approach
should enhance cancer cell death but still requires formal test-
ing. Our studies and others strongly support a link between PML
and p53 whereby these proteins exist in a positive regulatory loop
(Louria-Hayon et al., 2003; Bernardi et al., 2004; Alsheich-Bartok
et al., 2008). Therefore the combined approach of restoring PML
together with p53 (e.g., by using nutlin) should be tested. The
tailoring of PML therapies to target multiple defined genetic mal-
functions in individual cancers offers an exciting novel approach
to inhibit cancer cell growth.
THERAPIES TO TARGET ONCOGENIC PML ACTIVITIES
TARGETING PML-RARα TO TREAT ACUTE PROMYELOCYTIC LEUKEMIA
Generation of the PML-RARα oncogenic fusion protein disrupts
the normal functions of PML and RARα and is the driving path-
ogenic event in APL (de Thé et al., 1991; Rego et al., 2000;
de Thé and Chen, 2010). PML-RARα impairs the assembly of
PML-NBs and represses the expression of key regulatory genes
involved in myeloid differentiation (Daniel et al., 1993; Zhu et al.,
2002).
As2O3 and ATRA have been extensively used in the clinic as
anti-APL therapy and have the overlapping effect of targeting
and inducing the degradation of the PML-RARα fusion protein,
thereby overcoming the differentiation block and restoring the
senescence program in APL cells (Chen et al., 1997; Shao et al.,
1998; Ferbeyre, 2002) (Figure 3). As2O3 is highly effective in the
treatment APL and superior to ATRA in terms of its ability to
achieve molecular remissions. As2O3 has been used as a single
agent, and in combination with ATRA and chemotherapy achiev-
ing long term disease-free survival in up to 90% of APL patients
(Hu et al., 2009; Ravandi et al., 2009; Mathews et al., 2010; Powell
et al., 2010; Ghavamzadeh et al., 2011; Iland et al., 2012).
All-trans retinoic acid and As2O3 have the effect of restoring
the normal distribution pattern of the PML associated NBs in
APL (Koken et al., 1994; Weis et al., 1994; Muller et al., 1998b).
In contrast to the NB reorganization induced by ATRA, As2O3
also causes swelling of the structures followed by a loss of PML
staining. This may be the result of As2O3 inducing the attachment
of multiple SUMO-1 molecules to PML (Muller et al., 1998a,b).
As2O3 targets PML to induce degradation of both the PML-RARα
fusion protein and PML (Lallemand-Breitenbach et al., 2012). The
action of As2O3 is attributed to a combination of direct binding
to PML and a more general oxidant effect (Jeanne et al., 2010;
Zhang et al., 2010) (Figure 3). The inherent high ROS levels of
APL cells contribute to their sensitivity to As2O3 (Yi et al., 2002;
Li et al., 2008). Direct arsenic binding to PML results in topo-
logical changes in the RING domain enhancing the binding of
the SUMO-conjugating enzyme (Jeanne et al., 2010; Zhang et al.,
2010). As2O3 treatment also induces phosphorylation of the PML
protein through a mitogen-activated protein (MAP) kinase path-
way, which promotes efficient SUMOylation of PML (Hayakawa
and Privalsky, 2004). Poly-SUMOylated PML is recognized by
FIGURE 3 |Targeting oncogenic PML in acute promyelocytic leukemia.
Both agents target the PML-RARα fusion protein for degradation. ATRA
promotes RARα-target gene transcription to overcome the differentiation
block while As2O3 induces oxidant stress and directly binds PML to cause
partial differentiation and apoptosis of APL cells and more effectively
eradicate leukemia-initiating cells.
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the SUMO-dependent ubiquitin ligase RNF4, poly-ubiquitinated,
and degraded (Lallemand-Breitenbach et al., 2008; Tatham et al.,
2008). Furthermore, As2O3 also induces apoptosis via oxidant
stress (Miller et al., 2002).
TARGETING GOF PML ACTIVITIES IN NON-HEMATOPOIETIC
MALIGNANCIES
Beyond APL, we have reported another example of what appears to
be PML gain of function (GOF). In the background of mutant p53,
PML tumor suppression cannot only be lost, but its activities can
be conscripted to provide growth advantage. In fact, when PML
was knocked down in these cancer cells they lapsed into growth
arrest (Haupt et al., 2009). It is in this context that arsenic triox-
ide treatment of mutant p53 cancer cells is interesting, because
although the drug has been demonstrated to target mutant p53
for proteasomal degradation (Yan et al., 2011), the activity against
PML in this context has yet to be demonstrated, and neither has
the consequence for cell viability.
Interestingly, PML was recently found to be elevated in a
subpopulation of triple negative breast cancer patients and this
correlated with reduced survival and poor prognosis (Carracedo
et al., 2012). The functional studies revealed that in this context
PML was able to simultaneously inhibit acetylation of peroxisome
proliferator-activated receptor (PPARγ) co-activator 1A and acti-
vate PPAR signaling and fatty acid oxidation, which resulted in
increased ATP. It will be critical to define the PML profile in these
breast cancers where gain of pro-survival functions is apparent
and fascinating to explore whether PML targeted therapy such as
As2O3 has an application in these specific cancers. In addition,
targeting the pathways activated by this elevated PML (i.e., fatty
acid oxidation) may hold promise for therapy. However, targeting
this pathway will need careful consideration as it is also involved
in PML-dependent hematopoietic stem cell (HSC) maintenance
(Ito et al., 2012).
TARGETING ELEVATED LEVELS OF PML TO ERADICATE LEUKEMIC STEM
CELLS
Promyelocytic leukemia plays a key role in the maintenance of
HSCs and leukemia-initiating cells (LICs) (Ito et al., 2008). Murine
Pml−/− HSCs are not quiescent in the bone marrow of recipi-
ent mice and lacked long term repopulating capacity following
transplantation. LICs share features of HSCs such as self-renewal,
pluripotency, and quiescence (Reya et al., 2001; Hope et al., 2004;
Holtz et al., 2007).
Quiescent chronic myeloid leukemia (CML) stem cells are resis-
tant to conventional therapy including Bcr-Abl tyrosine kinase
inhibitors and can be a source of relapse (Holtz et al., 2007). Unlike
many other hematological malignancies, PML is highly expressed
in CML particularly in more primitive CD34 positive cells (Ito
et al., 2008). Indeed PML expression is an adverse prognostic fac-
tor in CML and being investigated as a potential therapeutic target
in this disease. In a CML mouse model, Pml−/− LICs undergo
intensive cycling resulting in impairment of LIC maintenance and,
in contrast to Pml wt cells, failed to initiate a CML-like disease
after serial bone marrow transplantation procedures (Ito et al.,
2008). By down-regulating PML, As2O3 also induces cell cycling
of quiescent LICs and enhances cytarabine-mediated apoptosis to
eradicate these cells in a serial transplantation model (Ito et al.,
2008).
FUTURE DIRECTIONS
Over the last decade, immense progress has been made regard-
ing our understanding of molecular pathways regulating PML
stability. Major post-translational modifications such as phospho-
rylation, acetylation, SUMOylation, and ubiquitination and their
interactions have been extensively studied in normal and cancer
cells. Although we have identified certain kinases and E3 ubiq-
uitin ligases of PML, less is known about potential phosphatases
and deubiquitinases, which are likely to play important regula-
tory functions. Another key limitation in our understanding of
PML is the shortage of information about isoform specific effects
and the potential problem with protecting and activating can-
cer promoting or cancer suppressing proteins. Hence, the new
generation of mouse models specific for PML isoforms will be
absolutely necessary to address these important issues. Treating of
APL patients with As2O3 is usually very effective as it specifically
targets the pathogenic PML-RARα fusion protein for degradation
and reactivates functional PML. However, there is a proportion
of APL patient that remains resistant and therefore novel thera-
pies are required. Clearly, the restoration of PML to inhibit cancer
growth emerges as a promising targeted strategy (Wolyniec et al.,
2012a) that could be applied to many cancer types, given that
PML plays a central tumor suppressive role in a wider range of
human cancers than previously appreciated. Importantly it could
be combined with currently used therapies such as chemother-
apy, IFN, or IL-6 treatment, which are known to induce PML.
Pertinently currently there are emerging several potentially drug-
gable targets such as CK2, BMK1, KLHL20, and E6AP that has
been demonstrated to negatively regulate PML stability in various
pre-clinical cancer models. Further studies are required to eval-
uate the anti-cancer efficiency of the specific inhibitors of these
molecules such as XMD8-92 in multiple pre-clinical models and
eventually in clinical trials. However, there is a caveat concerning
targeting of BMK1, related to the recent finding reporting that
inhibition of BMK1 can stimulate EMT and cell migration (Chen
et al., 2012a). As illustrated in this review one needs to carefully
consider tissue type, genetic background, and stage of the disease
in order to trigger PML for the benefit of patients with minimal
possible side-effects. It becomes apparent that PML is regulated
by different molecules in different cancer types, e.g., by E6AP in
B-cell lymphoma (Wolyniec et al., 2012b), CK2, and PIAS1 in
NSCL cancer (Scaglioni et al., 2006; Rabellino et al., 2012) whereas
KLHL20/Pin1 in prostate adenocarcinoma (Yuan et al., 2011).
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